XOMA Royalty Corp (XOMA) Form 8-K — May 18, 2026
XOMA Royalty Corporation filed an 8-K reporting an amendment to its previously disclosed merger agreement with Ligand Pharmaceuticals Incorporated. The amendment, dated May 16, 2026, formally adds XOMA Royalty Holdings Corporation (HoldCo) as a party to the agreement to facilitate a holding company reorganization. This structural change allows Merger Sub to merge with HoldCo, which will survive as a wholly-owned subsidiary of Ligand Pharmaceuticals.
Price after filing
1 day: -0.2%7 days: +0.4%30 days: +0.3%
Close on the filing date to close N calendar days later (from $41.64). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.